Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled,
parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics
(PK), and pharmacodynamics (PD) of Bimekizumab compared with placebo in adult subjects with
moderate to severe chronic plaque psoriasis in order to guide the selection of doses and
clinical indices in the Phase 3 development program.